Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative products for ophthalmic and neurosurgical applications, has introduced the CMC
V, the next generation of the Codman
electrosurgical generator. Codman & Shurtleff, Inc. is the exclusive distributor of the CMC
V. CMC and Codman are registered trademarks of Johnson & Johnson Corporation.
“The new CMC
V is a state-of-the-art, digitally controlled electrosurgical generator that provides surgeons with significant advancements in controls for use with bipolar foot and hand-operated, cutting and coagulating instruments,” stated Dave Hable, President and CEO of Synergetics USA, Inc. “The launch of this next generation electrosurgical generator, designed and built by our Company, demonstrates our long-standing relationship with Codman, a global leader in neuroscience and neurovascular devices and solutions.”
New features of the CMC
V include touch screen technology, select local language display and messaging, and the ability to customize eight end-user profiles to suit surgeon preferences or procedural preferences.
“We are very excited about the potential benefits that the CMC
V and our disposable bipolar instruments can bring to doctors and hospitals. The CMC
V will be available in select U.S. markets beginning late 2010, and is expected to be available in Europe by early next year,” concluded Mr. Hable.
About Synergetics USA, Inc.
Synergetics USA, Inc. (“Synergetics USA” or the “Company”) is a leading supplier of precision microsurgery instrumentation. The Company’s primary focus is on the microsurgical disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent sales organizations and important strategic alliances with market leaders. The Company’s product lines focus upon precision engineered, microsurgical, hand-held instruments and the delivery of various energy modalities for the performance of less invasive microsurgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company’s website address is
Some statements in this release may be “forward-looking statements” for the purposes of the Private Securities Litigation Reform Act of 1995.
In some cases forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions.
Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These factors, risks and uncertainties are discussed in Synergetics’ Annual Report on Form 10-K for the year ended July 31, 2010, as updated from time to time in our filings with the Securities and Exchange Commission.